

=> b reg  
FILE 'REGISTRY' ENTERED AT 07:50:52 ON 08 MAR 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 MAR 2007 HIGHEST RN 925228-12-2  
DICTIONARY FILE UPDATES: 6 MAR 2007 HIGHEST RN 925228-12-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> d que sta 17  
L4 ( 35972)SEA FILE=REGISTRY ABB=ON PLU=ON >=2 NC5-C6/ES  
L5 STR  
Hy---N---Hy---N---Hy  
1 2 3 4 5

#### NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED  
ECOUNT IS UNLIMITED AT 2 4

#### GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 5

#### STEREO ATTRIBUTES: NONE

L6 ( 330)SEA FILE=REGISTRY SUB=L4 SSS FUL L5  
L7 47 SEA FILE=REGISTRY ABB=ON PLU=ON L6 AND NCNC3/ES

=> b hcap  
FILE 'HCAPLUS' ENTERED AT 07:51:03 ON 08 MAR 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.



FILE COVERS 1907 - 8 Mar 2007 VOL 146 ISS 11  
FILE LAST UPDATED: 7 Mar 2007 (20070307/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitrn fhitstr l17 tot


L17	ANSWER 1 OF 2	HCAPLUS	COPYRIGHT 2007 ACS on STN
AN	2002:754380	HCAPLUS	
DN	137:263071		
TI	Preparation of trisubstituted 2,4,6-triamino[1,3,5]triazines as anti-telomerase agents		
IN	Mailliet, Patrick; Laoui, Abdelazize; Riou, Jean-Francois; Doerflinger, Gilles; Mergny, Jean-Louis; Hamy, Francois; Caulfield, Thomas		
PA	Aventis Pharma S.A., Fr.		
SO	PCT Int. Appl., 208 pp.		
	CODEN: PIXXD2		
DT	Patent		
LA	French		
FAN.CNT	1		
PATENT NO.		KIND	DATE
-----		-----	-----
PI	WO2002076975	A1	20021003 2002WO-FR01005 20020322
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	FR---2822468	A1	20020927 2001FR-0003916 20010323
	CA---2442012	A1	20021003 2002CA-2442012 20020322
	EP---1373252	A1	20040102 2002EP-0720068 20020322
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
	JP2004524349	T	20040812 2002JP-0576233 20020322
	US2003087931	A1	20030508 2002US-0103883 20020325
	US---6887873	B2	20050503
	US2005070571	A1	20050331 2004US-0993637 20041119
PRAI	2001FR-0003916	A	20010323
	2001FR-0010370	A	20010802
	2001US-332009P	P	20011123
	2002WO-FR01005	W	20020322
	2002US-0103883	A3	20020325
OS	MARPAT 137:263071		
GI			



- AB** Title compds. I [A = XR<sub>1</sub>R<sub>2</sub>; X = N, O, S, alkyl radical; R<sub>1-2</sub> = H, alkyl, heterocyclyl, etc.; R<sub>3-3'</sub> = H, alkyl, isoquinolinyl, quinolinyl, etc.; Ar<sub>1-2</sub> = (un)substituted Ph, etc., and derivs. thereof] were prepared For instance, 2,4-bis[(4-(dimethylamino)-2-methylquinolin-6-yl)amino]-6-chloro[1,3,5]triazine (prior art) was reacted with N,N-dimethyl-1,3-propanediamine in DMF with K<sub>2</sub>CO<sub>3</sub> for 15 h at 100° to afford II. Examples include evaluation of all compds. of the invention for telomerase activity. I are anti-cancer agents.
- IT** **462649-59-8P**, 2-[(4-Amino-2-methylquinolin-6-yl)amino]-4-[(4-amino-2-methylquinolin-6-yl)amino]-6-[4-(pyrimidin-4-yl)piperazinyl]triazine  
**462649-65-6P**, 2-[(4-Amino-2-methylquinolin-6-yl)amino]-4-[(4-amino-2-methylquinolin-6-yl)amino]-6-[4-(pyrimidin-2-yl)piperazinyl]triazine  
**462649-99-6P**, 2-[(4-Amino-2-methylquinolin-6-yl)amino]-4-[(4-amino-2-methylquinolin-6-yl)amino]-6-[4-(pyrimidin-2-yl)amino]triazine  
**462650-15-3P**, 2-[(4-Amino-2-methylquinolin-6-yl)amino]-4-[(4-amino-2-methylquinolin-6-yl)amino]-6-[(4,6-dimethylpyrimidin-2-yl)oxy]triazine  
**462650-17-5P**, 2-[(4-Amino-2-methylquinolin-6-yl)amino]-4-[(4-amino-2-methylquinolin-6-yl)amino]-6-[(pyrimidin-2-yl)oxy]triazine  
**462650-39-1P**, 2-[(4-Amino-2-methylquinolin-6-yl)amino]-4-[(4-amino-2-methylquinolin-6-yl)amino]-6-[(pyrimidin-2-yl)sulfanyl]triazine  
**462650-41-5P**, 2-[(4-Amino-2-methylquinolin-6-yl)amino]-4-[(4-amino-2-methylquinolin-6-yl)amino]-6-[(4,6-dimethylpyrimidin-2-yl)sulfanyl]triazine **462650-96-0P**, 2-[(4-Dimethylamino-2-methylquinolin-6-yl)amino]-4-[(4-dimethylamino-2-methylquinolin-6-yl)amino]-6-[(pyrimidin-2-yl)amino]triazine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
     (preparation of trisubstituted 2,4,6-triamino[1,3,5]triazines as anti-telomerase agents)
- IT** **462649-59-8P**, 2-[(4-Amino-2-methylquinolin-6-yl)amino]-4-[(4-amino-2-methylquinolin-6-yl)amino]-6-[4-(pyrimidin-4-yl)piperazinyl]triazine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
     (preparation of trisubstituted 2,4,6-triamino[1,3,5]triazines as anti-telomerase agents)

RN 462649-59-8 HCAPLUS

CN 4,6-Quinolinediamine, N6,N6'-(6-[4-(4-pyrimidinyl)-1-piperazinyl]-1,3,5-triazine-2,4-diyl)bis[2-methyl- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:416931 HCAPLUS

DN 135:33495

TI Arylamine derivatives and their use as anti-telomerase agent

IN Mailliet, Patrick; Riou, Jean-Francois; Mergny, Jean-Louis; Laoui, Abdelazize; Lavelle, Francois; Petitgenet, Odile

PA Aventis Pharma S.A., Fr.

SO PCT Int. Appl., 66 pp.

CODEN: PIXXD2


DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2001040218	A1	20010607	2000WO-FR03310	20001127 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR---2801588	A1	20010601	1999FR-0015031	19991129 <--
	FR---2801588	B1	20020301		
	CA---2392507	A1	20010607	2000CA-2392507	20001127 <--
	BR2000015992	A	20020806	2000BR-0015992	20001127 <--
	EP---1244650	A1	20021002	2000EP-0985339	20001127 <--
	EP---1244650	B1	20030625		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	HU-200204429	A2	20030428	2002HU-0004429	20001127 <--
	JP2003515604	T	20030507	2001JP-0541902	20001127 <--
	EE-200200263	A	20030616	2002EE-0000263	20001127 <--
	AT---243692	T	20030715	2000AT-0985339	20001127 <--
	PT---1244650	T	20031128	2000PT-0985339	20001127 <--
	ES---2202206	T3	20040401	2000ES-0985339	20001127 <--
	US---6645964	B1	20031111	2000US-0722361	20001128 <--

NO2002002528 A 20020528 2002NO-0002528 20020528 <--  
 ZA2002004266 A 20030828 2002ZA-0004266 20020528 <--  
 BG---106753 A 20030228 2002BG-0106753 20020529 <--  
 US2004053966 A1 20040318 2003US-0658394 20030910 <--  
 PRAI 1999FR-0015031 A 19991129 <--  
 2000FR-0010561 A 20000811 <--  
 2000US-176632P P 20000119 <--  
 2000US-218059P P 20000713 <--  
 2000WO-FR03310 W 20001127  
 2000US-0722361 A3 20001128 <--  
 OS MARPAT 135:33495  
 AB Nitrogen heterocycles, especially diaminotriazines, were prepared for use as telomerase inhibitors and anticancer agents. Thus, 2-amino-4,6-dichloro-1,3,5-triazine was treated with 1-methyl-4,6-quinaldinium chloride hydrochloride to give 2-amino-4,6-bis(1-methyl-4-amino-6-quinaldinio)amino-1,3,5-triazine dichloride hydrochloride which was converted to its free base. The free base had a telomerase-inhibiting IC50 of 0.25 μM and a cytotoxic IC50 of 0.59-1.9 μM.  
 IT 343876-24-4P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of triazinediamine derivs. as telomerase inhibitors and antitumor agents)  
 IT 343876-24-4P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of triazinediamine derivs. as telomerase inhibitors and antitumor agents)  
 RN 343876-24-4 HCPLUS  
 CN 4,6-Quinolinediamine, N6,N6'-2,4-pyrimidinediylbis[2-methyl-, trihydrochloride (9CI) (CA INDEX NAME)



• 3 HCl

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=&gt; d his

(FILE 'REGISTRY' ENTERED AT 07:08:07 ON 08 MAR 2007)  
DEL HIS Y  
ACT J394C22/A

```
-----
L1  ( 35972)SEA FILE=REGISTRY ABB=ON PLU=ON >=2 NC5-C6/ES
L2          STR
L3          330 SEA FILE=REGISTRY SUB=L1 SSS FUL L2
-----
          ACT J394C22A/A
-----
L4  ( 35972)SEA FILE=REGISTRY ABB=ON PLU=ON >=2 NC5-C6/ES
L5          STR
```

L6 ( 330)SEA FILE=REGISTRY SUB=L4 SSS FUL L5  
L7 47 SEA FILE=REGISTRY ABB=ON PLU=ON L6 AND NCNC3/ES  
-----

FILE 'HCAPLUS' ENTERED AT 07:10:07 ON 08 MAR 2007  
L8 6 L7  
L9 1 (US2004053966 OR US6645964)/PN OR (US2003-658394 OR US2000-7223  
E MAILLIET P/AU  
L10 73 E3-4  
E RIOU J/AU  
L11 235 E3-4,E9-12  
E MERGNY J/AU  
L12 86 E4-5  
E LAOUI A/AU  
L13 30 E3-5  
E LAVELLE F/AU  
L14 88 E3,E8  
E PETITGENET O/AU  
L15 5 E3-4  
L16 1 (FR2000-10561 OR FR99-15031)/AP, PRN  
L17 2 L8 AND L9-16  
L18 4 L8 NOT L17

FILE 'MEDLINE' ENTERED AT 07:42:12 ON 08 MAR 2007  
L19 0 L7

FILE 'EMBASE' ENTERED AT 07:42:23 ON 08 MAR 2007  
L20 0 L7

FILE 'BIOSIS' ENTERED AT 07:42:30 ON 08 MAR 2007  
L21 0 L7

FILE 'USPATFULL, USPAT2' ENTERED AT 07:42:36 ON 08 MAR 2007  
L22 10 L7  
L23 2 L22 AND L9,L16  
L24 8 L22 NOT L23  
L25 0 L24 AND (PY<=2000 OR AY<=2000 OR PRY<=2000)

FILE 'TOXCENTER' ENTERED AT 07:45:39 ON 08 MAR 2007  
L26 5 L7

=>